Introduction
============

Kruppel-like factor 4 (KLF~4~) is a member of the family of zinc-finger transcription factor, which is expressed in various human tissues. It is well known as one of the four factors of the induction to pluripotent stem cells (iPSCs) ([@B23]). KLF~4~ can regulate multiple important biological processes such as neuroinflammation, oxidative stress, proliferation, differentiation, and apoptosis ([@B40]; [@B52]; [@B107]; [@B54]; [@B97]). Amounts of previous studies focused on KLF~4~'s role in cancer development and progression ([@B39]; [@B98]). KLF~4~ is a dual-function transcription factor, which can exert its role as an oncogene or a tumor suppressor gene depending on the cancer type or cancer stage ([@B20]). It can activate or inhibit transcription of genes involved in cell proliferation, differentiation and apoptosis ([@B18]). KLF~4~ can collaborate with other reprogramming factors to convert the somatic cells into iPSCs and inhibit the differentiation of stem cells ([@B86]; [@B90]). This provides therapeutic prospects for vascular diseases, immune diseases, anorexia and other diseases ([@B36]; [@B50]; [@B56]). Moreover, KLF~4~ can play a widely regulatory role in the central nervous system (CNS). Several studies indicate that KLF~4~ is linked to multiple neurological disorders, including Alzheimer's disease (AD), epilepsy, Parkinson's disease, hydrocephalus and schizophrenia ([@B64]; [@B96]; [@B31]; [@B58]; [@B45]).

AD is one of the most common chronic neurodegenerative diseases, which leads to cognitive and memory impairments, various mental symptoms and behavioral abnormality and progressive dementia is the most common clinical feature ([@B37]). The current confirmed pathogenic factors of AD include the formation of senile plaques induced by abnormal amyloid-β (Aβ) deposition and the neurofibrillary tangles or dystrophic neuritis induced by tau accumulation ([@B67]; [@B80]). In addition, AD can be also affected by genetic factors. However, the elicit pathogenesis is still obscure. The most prevalent drugs for AD treatment include neurotransmitter enhancers, anti-Amyloid agents, neuroprotective peptides, and other drugs ([@B6]). Notably, several studies have showed that KLF~4~ played a significant role in the pathogenesis of AD. In this review, we focus on the regulatory role of KLF~4~ in neuroinflammation, neuronal apoptosis, axonal regeneration, and iron accumulation to explain the association between KLF~4~ and the pathogenesis of AD, which might provide insights into the cellular and molecular mechanisms of neurodegenerative disorders.

The Biological Characteristics of KLF~4~
========================================

KLF~4~ is a zinc finger-containing nuclear protein, isolated from NIH 3T3 library and located in the cell nucleus. It was first identified and characterized by [@B78]. The molecular mass of human KLF~4~ is 55kD and it is located on the chromosome 9q31. KLF~4~ covers a 6.3 kb gene segment and has five exons. Its cDNA coding region encodes a polypeptide consisting of 470 amino acid residues ([@B100]; [@B23]). The carboxy terminus of KLF~4~ has a DNA binding structure region containing three Cys2His2 (C2H2) type zinc finger structures, which are formed by 81 highly conserved amino acids. It regulates transcription by high affinity with CACCC elements and GC-rich target gene DNA sequences ([@B79]; [@B62]). Most of the DNA-binding sites of KLF~4~ are located within the zinc finger region, including N-terminal transcription activation domain for proteins interacting, C-terminal zinc finger structure for DNA binding and transcription inhibition zone ([@B4]). KLF~4~ is involved in regulating the expression of many endogenous genes ([@B79]). There is a highly variable transcriptional regulatory domain at the amino terminus of KLF~4~. The amino acid residues located between the 91 and the 117 amino constitute a transcriptional activation domain, which is rich in proline and serine, while a transcriptional repression domain also exists. Therefore, KLF~4~ has two adverse effects: activating and inhibiting gene transcription ([@B100]; [@B92]).

During the embryonic development, KLF~4~ was higher expressed in the late stage of embryonic development. While in mature tissues and organs, KLF~4~ is mainly expressed in the gastrointestinal tract, oral cavity, skin epidermis, vascular endothelium and kidney, and is less expressed in the brain ([@B73]; [@B22]; [@B49]; [@B11]; [@B32]; [@B5]). It is thought to play significant role in regulating cell proliferation and differentiation. Besides, KLF~4~ can also regulate cell cycle. KLF~4~ can activate P21 in a P53-dependent manner ([@B108]). In addition, It was found that KLF~4~ (--/--) cells entered senescence phase earlier than KLF~4~ (+/+) cells, which can be explained by the less antioxidant gene expression and higher reactive oxygen species (ROS) level in KLF~4~ (--/--) cells. ROS can increase p53 and p21 expression and subsequently promote the DNA damage ([@B51]). It was found that PRMT5 can elevate the KLF~4~ expression in protein levels. PRMT5 was reported to increase the transcription of p21 and decrease the expression of bax via inhibiting KLF~4~ ubiquitylation ([@B35]). Furthermore, numerous studies have demonstrated that KLF~4~ is involved in regulation of apoptosis of neurons ([@B42]; [@B14]; [@B82]). Physiological regulatory role of KLF~4~ that we have known are still little and further investigations are needed.

Role of KLF~4~ in AD
====================

It is well established that AD is mainly characterized by memory and cognitive impairments and executive dysfunction ([@B25]). Many studies have demonstrated that neuronal apoptosis and synaptic dysfunction are pathological basis of the decline of cognitive function ([@B7]; [@B30]; [@B101]). The accumulated damage of Aβ deposition, oxidative stress and iron accumulation can lead to neuronal dysfunction and apoptosis of AD patients. Several studies have shown that KLF~4~'s regulatory role appears to be crucial in CNS. Considering that KLF~4~ was reported to regulate neuronal apoptosis, synaptic regeneration, oxidative stress and neuroinflammation, the relationship between KLF~4~ and the pathogenesis of AD might be a potential novel target for AD treatment.

Role of KLF~4~ in Neuroinflammation
-----------------------------------

Amounts of clinical studies have shown that Aβ can aggregate and is the main component of the extracellular deposits of the brain tissue of AD patients, which can impair the surrounding synapses and neurons, and lead to neuronal death. Abnormal secretion or excessive production of Aβ leads to pathological changes of AD, so Aβ deposition is the core link of AD ([@B68]). In addition, studies have shown that excessive Aβ deposition can stimulate glial cells to secrete ROS and other influencing factors, leading to oxidative stress. It was known that oxidative stress can stimulate the production of Aβ. Therefore, Aβ and oxidative stress can interact with each other and affect the progression of AD ([@B9]).

KLF~4~ was reported as a potential modulator and has a great effect on inflammation by mediating macrophages and endothelial cells (**Figure [1](#F1){ref-type="fig"}**) ([@B102]; [@B38]; [@B99]). In the CNS, excessive and chronic inflammatory reactions can cause damage of neuron and neurogliocyte. It was recently demonstrated that the KLF~4~ expression positively correlated with Aβ42-induced neuroinflammation. In microglial BV2 cells, oligomeric Aβ42 can increase KLF~4~ expression, which is mediated by activated P53 ([@B45]). Under inflammatory conditions, such as Aβ accumulation, the release of pro-inflammatory cytokines may be stimulated in the generation of AD ([@B28]). Neurotoxicity potency and pro-inflammatory potency of soluble Aβ42 oligomers is relatively higher than insoluble fiber deposit ([@B74]; [@B93]). Silence of KLF~4~ is able to restore Aβ42-mediated neuroinflammation, and overexpression of KLF~4~ can exacerbate Aβ42-mediated neuroinflammation ([@B45]). Aβ accumulation induces activation of astrocytes and microglia ([@B69]). Activated astrocytes can enhance the neuroinflammation by releasing pro-inflammatory factors such as IL-1, IL-6, and TNF-α ([@B70]; [@B19]). The vicious cycle of inflammatory responses eventually leads to dysfunction and neuronal apoptosis.
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KLF4 plays a crucial role in regulating pro-inflammatory signals. In glial cells, gemfibrozil-induced KLF4 activation increases suppressor of cytokine signal 3 (SOCS3) via PI3-kinase-AKT pathway ([@B24]). The SiRNA-mediated knockdown of KLF4 could attenuate the level of SOCS in astroglia and microglia of mice, which could subsequently affect the expression of inflammatory gene ([@B40]; [@B24]). In addition, SOCS deletion can promote the survival of injured neurons and promote axon regeneration ([@B81]; [@B85]). And KLF~4~ positively regulates the production of IL-1β or other pro-inflammatory markers. It positively regulates cyclooxygenase-2 (Cox-2) and negatively regulates inducible nitric oxide synthase (iNOS) ([@B41]). In addition, KLF~4~ is an important regulatory factor for monocyte differentiation and a potential target for immune regulation ([@B3]). Therefore, KLF~4~ might promote neuroinflammation by regulating these negative regulators.

It is worth mentioning that in Parkinson's disease model, KLF~4~ can promote MPP+-induced oxidative stress and neurotoxicity, and then increase neuronal apoptosis and delay the cell proliferation ([@B10]). Oxidative stress is an imbalance between peroxidation and antioxidation. Free radicals can cause changes in different macromolecules, leading to cell damage, cell aging and tissue damage ([@B60]; [@B57]). Oxidative stress can aggravate early inflammation and Aβ production and then aggravate AD ([@B8]). Therefore, KLF~4~ may be involved in oxidative stress in AD.

These findings imply KLF~4~ a key role in mediating neuroinflammation by activating the microglia and the consequently release of pro-inflammatory cytokines. It has potential to enhance neuroinflammation. So far, many studies on the pathogenesis of AD have focused on neuroinflammation. As a potential target for immune regulation, KLF~4~ can promote the inflammatory responses of microglia via affecting related negative regulators, which has a great effect on the development of AD.

Role of KLF~4~ in Apoptosis
---------------------------

Neurodegenerative changes include gradual loss of neurons and synapses in the representative brain regions, such as the cerebral cortex, hippocampus and other subcortical regions. The functional impairments of CNS induced by neuronal loss are permanent ([@B12]). Sustained oxidative stress can lead to neuronal apoptosis ([@B94]). A large number of studies have confirmed that AD is closely related to oxidative stress ([@B44]; [@B105]). It was found that chronic oxidative stress can enhance the expression of Phospholipase A2 group 3 (Pla2g3) in astrocytes and disrupt the balance of Aβ, and consequently lead to the development of AD ([@B105]).

Many studies have demonstrated that KLF~4~ plays an important role in inhibiting the development of oxidative stress ([@B77]; [@B51]). It was found that KLF~4~ can promote the cells apoptosis induced by H~2~O~2~, this action is likely to be caused by increased bax expression and decreased bcl-2 expression ([@B48]). Quercetin could reduce KLF~4~ expression in human neuroblastoma SH-SY5Y cells, and increase the expression of bcl-2/bax ratio. Furthermore, Quercetin can moderate the apoptosis rate of SH-5YSY cell and reduce caspase-3 enzyme activity ([@B95]). A recent study investigated the neuroprotective effect of mitogen-activated protein (MAP) kinase 5 (ERK5) against oxidative stress. Activation of ERK5 can partially reduce H~2~O~2~-induced hippocampal neurons death and increase the NGF- and PC-induced neuroprotection ([@B84]). Nils et al. used a mutant of MEK5 (MEK5D) to study the ERK5-activated transcription and functional responses in human endothelial cells, and identified KLF~4~ was a novel downstream ERK5 target ([@B59]). It was found that overexpression of KLF~4~ can suppress TNF-mediated inflammatory responses and reduce leukocyte adhesion and basal cell apoptosis. These results confirm that KLF~4~ has anti-inflammatory and anti-apoptotic properties ([@B59]). Subsequent experiments have demonstrated that the disappearance of cerebral cavernous malformation 1 (CCM1) in endothelial cells activates ERK5 via MEKK3-MEK5 signal pathway and increases KLF~4~ expression ([@B15]). ERK5 plays a mediating role in preconditioning (PC) and nerve growth factor (NGF) up-regulated the expression of KLF~4~ ([@B84]). In addition, RNAi-mediated knocking-down of KLF~4~ can also reduce NGF- or PC-induced neuroprotection. Overexpression of KLF~4~ leads to higher bcl-2/bax ratio in H2O2-stressed cells ([@B84]). Over-expressed KLF~4~ accelerates changes in bcl-2 and bax by combining with its corresponding promoter ([@B48]). ERK5/KLF~4~ cascade may act as a pivot in various pathways which protect neurons from oxidative stress-induced death ([@B84]).

Oxidative stress has been considered to be closely related to many degenerative diseases. KLF~4~ plays significant roles in maintaining genomic stability in oxidative stress. KLF~4~ and ERK5 act together to protect neurons from oxidative stress-induced apoptosis. Therefore, KLF~4~ may act as a therapeutic target to act against oxidative stress when it activated. It has been reported that statin drugs can activate ERK5, leading to the expression of KLF~4~ and its dependent genes ([@B59]), but the mechanism remains unclear, and KLF~4~ related upstream and downstream target genes are less studied in oxidative stress, there is a need for further study.

Role of KLF~4~ in Axon Regeneration
-----------------------------------

Early axon loss is a common feature of neurodegenerative diseases. Synaptic loss and transport impairment in AD can cause cognitive impairments ([@B33]; [@B13]). The degree of declarative memory damage is related to the synaptic density in the hippocampus and cortex. Soluble Aβ oligomers reduce glutamate uptake and promote synaptic dysfunction, disrupting synaptic plasticity ([@B47]). Therefore, it is particularly important to study how to repair the axons in the CNS. In retinal ganglion cells, axons have a strong ability to grow and regenerate during early development, but in the CNS of adult mammals, axons lose their regeneration capacity and the neurons may graduate to die or atrophy ([@B26]; [@B27]).

KLF~4~ plays an important role in inhibiting axon growth. In embryonic RGCs, overexpression of KLF~4~ can reduce the percentage of neurite elongation, the length of axons and dendrites, and the neurite branching. Besides, it was found that the overexpression of KLF~4~ can reduce long-term postnatal axon growth rates but failed to reduce short-term axon growth rates ([@B55]; [@B83]). Later studies have found that the axon bundles of KLF~4~--cKO mice were thicker than control mice ([@B21]). In addition, removal of KLF~4~ expression during development can increase the reproductive potential of adult RGCs. In addition, KLF~4~ lacking the c-terminal DNA binding domain had no effect on the axon growth. There was no impact on the survival of cells after retinal ganglion cells were injured if the KLF~4~ was knocking-out ([@B55]).

KLF~4~ can also affect the axonal regeneration. A recent study reported that the decrease of KLF~4~ expression in adult retinal ganglion cells promoted axon regeneration through JAK-STAT3 pathway ([@B66]). KLF~4~ increased the phosphorylation of STAT3, and regulated the axon growth via JAK-STAT signaling ([@B65]). Under the treatment of cytokines, members of STAT family of proteins are phosphorylated at the carboxy-terminal tyrosine and serine sites within the cell to form a stable dimer. This modification enhances transcription of cell-associated genes ([@B104]). The interaction between KLF~4~ and STAT3 on cytokine-induced phosphorylation of tyrosin705 inhibits the expression of STAT3 by inhibiting the binding of STAT3 to DNA ([@B66]). KLF~4~ knockdown obviously improves axon's regeneration in retinal ganglion cells after injury of optic nerve, and prevents the nerve from injury after mild brain injury. The actions are mediated by a decrease in p-p53 and an increase in pSTAT3 levels. KLF~4~ positively regulates neuronal apoptosis via the p53 and JAK-STAT3 pathways, and KLF~4~ negatively regulates axonal repair via the JAK-STAT3 pathway ([@B14]).

Therefore, we hypothesized that in AD, axonal regeneration can be accomplished by altering the expression of KLF~4~ or altering intracellular related signaling pathways, and controlling AD progression by reducing missing axons or reducing axonal dysfunction. However, how to use the KLF~4~ transcription factor in potential therapeutics still needs further exploration.

Role of KLF~4~ in Iron Accumulation
-----------------------------------

Iron is widely found in biological systems, iron-related metalloproteinases play a key role in transporting oxygen, transferring electrons, and catalyzing biochemical reactions ([@B2]). However, any excess of iron beyond the normal physiological range can damage human health ([@B1]). Studies have found that iron content in the hippocampus is negatively correlated with the performance of memory tests ([@B17]). Increased iron load in the brain accelerates the formation of Aβ plaques and hyperphosphorylated tau tangles, while also enhancing oxidative stress ([@B63]). Iron, which has a high degree of permeability, promotes nerve growth and cell-to-cell connections during brain development ([@B16]).

A recent study demonstrated that physiological stress caused activation of the KLF~4~-HCP1 signaling pathway and increased heme uptake ([@B46]). Heme accounts for 95% of the functional iron in the human body. It is one of the main components of heme oxygenase ([@B34]; [@B43]). Increasing the activity of oxygenase-1 can delay oxidation of the aging brain ([@B91]; [@B75]; [@B43]). This has a relief effect on AD. Physiological stress induces glucocorticoid level rise, glucocorticoid increases heme carrier protein 1 (HCP1) expression via KLF~4~, and then HCP1 promotes heme uptake ([@B46]). Glucocorticoid and KLF~4~ regulate anti-inflammatory genes together, and cells with low glucocorticoid content cannot fully induce KLF~4~ expression ([@B76]). KLF~4~-induced increase in heme intake leads to iron accumulation in the brain. Iron promotes the release of ROS ([@B87]). Iron element enhances brain oxidative stress in rats under psychological stress ([@B103]). Therefore, HCP1 may be regulated by KLF~4~ and glucocorticoid together. Increasing HCP1 enhances heme uptake, which leads directly to iron accumulation in the brain, exacerbates oxidation, increases apoptosis or dysfunction and worsens brain damage.

It is generally accepted that the memory and learning disability are the main symptoms of AD. A large number of clinical data have shown that Aβ plaque load and iron accumulation response to the development of learning and cognitive dysfunction in AD ([@B89]). Recently published data has suggested that, high-dose iron increases Aβ deposition and attenuates learning and memory in mice ([@B29]). Clinical studies have shown that iron-containing microglia is found in the hippocampus of AD patients under magnetic resonance imaging ([@B106]). Microglia acquires iron from transferring or non-transferring, extracellular and intracellular sources ([@B53]). Selective and sustained KLF~4~ expression can be induced in the nucleus and cytoplasm of ischemic hippocampal reactive astrocytes ([@B61]). Studies have shown that KLF~4~ acts as a transcriptional repressor. It down-regulates the expression of ELK-3, and then ELK-3 inhibits the expression of HO-1 ([@B88]). Heme oxygenase-1 (HO-1) is a stress protein that degrades heme into bilirubin, free iron, and carbon monoxide. Up-regulation of HO-1 in astrocytes can lead to abnormal iron deposition and mitochondrial dysfunction in the brain, leading to decreased cognitive ability ([@B71], [@B72]). Therefore, KLF~4~ may be involved in the process of iron accumulation in astrocytes, exacerbating oxidation in AD and aggravating brain damage.

Conclusion
==========

KLF~4~ is commonly known to play a pivotal role in regulating cell proliferation, apoptosis, and differentiation. Previous studies have focused on the regulation of KLF~4~ in several important neurophysiological processes, including neuroinflammation, neuroprotection and synaptic regeneration. Recently, KLF~4~ has been found to play an important role in the pathogenesis of AD. In this article, we review the role of KLF~4~ in neuroprotection and neurogenesis in AD.

KLF~4~ is not only a regulator of regulation of cell proliferation and differentiation, but also a potential target for regulating immune responses. KLF~4~ may regulate negative inflammatory factors and promote inflammatory response, and have a great effect on the expression of astrocyte nuclear microglia. In addition, KLF~4~ and ERK5 can act together to exert neuroprotective actions. Furthermore, axon regeneration can be accomplished by altering the content of specific transcription factors, intracellular inhibitors, or altering intracellular signaling pathways. Knocking out KLF~4~ can enhance the axon regeneration and accelerate axon growth rate. Reduction of KLF~4~ expression promotes axon regeneration through the JAK-STAT3 pathway, and KLF~4~ promotes the JAK-STAT3 pathway to further axon regeneration. Therefore, KLF~4~ might be involved in the process of anti-inflammatory, anti-apoptosis, axon regeneration and iron accumulation in the CNS, which plays a pivotal role in the AD generation. These findings suggest that KLF~4~ represents a potential therapeutic target for AD. However, the deep cellular and molecular mechanisms of the effects of KLF~4~ on AD remain unclear and further investigations are needed.
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